Citations

Clear

511 citation(s) found for "Seth, N".

Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Gupta, Samir , Axell, Lisen, Burke, Carol A. , Chen, Lee-may, Chung, Daniel C. , Clayback, Katherine M, Felder, Seth , Giardiello, Francis M., Gustafson, Susan, Hagemann, Andrea R. , Hall, Michael J. , Idos, Gregory , Joseph, Nora, Kassem, Nawal , Kelly, Kaitlyn, Kieber‐Emmons, AnnMarie, Kupfer, Sonia S., Lang, Katie, Llor, Xavier , Markowitz, Arnold J. , Prats, Mariana Moreno, Niell‐Swiller, Mariana, Pirzadeh‐Miller, Sara , Samadder, N. Jewel , Shibata, David , Swanson, Benjamin , Szymaniak, Brittany M. , Welborn, Jeanna, Wiesner, Georgia L. , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Diwan, Zeenat, Samadder, Niloy Jewel, Gupta, Samir , Burke, Carol A , Hodan, Rachel , Weiss, Jennifer M. , Chung, Daniel C., Foda, Zachariah H. , Grady, William M. , Hampel, Heather , Katona, Bryson W , Outlaw, Darryl Alan , Stanich, Peter P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 695-711

10.6004/jnccn.2024.0061 | PMID 39689429 Get It

Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing. This manuscript also describes recent updates to these guidelines regarding de-implementation of colon cancer screening in individuals with CHEK2 pathogenic/likely pathogenic variants, based on the most up-to-date evidence regarding the association between CHEK2 pathogenic/likely pathogenic variants and colon cancer risk.
Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden
Zhang, Connie, McStocker, Samantha, Healey, Amanda, Kuypers, Nicholas, Chanpura, Mohin , Anwar, Hiba , Paulose, Jincy, Lee, Soyon , Seth, Puja , Yen, Glorian , Dingli, David , Healey, Amanda, Kuypers, Nicholas, Seth, Puja

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2327-2327

10.1182/blood-2024-211194 Get It

Background and significance: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition caused by a somatic mutation in the PIG-A gene, leading to complement-mediated hemolysis and severe complications such as anemia and thrombosis. Patients often experience fatigue, dyspnea, and abdominal pain, impacting their daily lives and emotional well-being. This study aims to comprehensively explore the impact of PNH on health-related quality of life (HRQoL), alongside real-world treatment utilization and symptom burden patterns, especially as new treatments become available to this patient population. These results are based on interim baseline data from currently enrolled study participants, providing an initial assessment of their PNH disease experience. This analysis does not include any data collected prospectively during the data collection period. Study design and methods: This ongoing, prospective, observational study (NCT06411626) aims to enroll at least 128 US-based participants aged 18 or older with PNH, regardless of treatment usage. Participants are recruited through clinician-based referrals, patient advocacy organizations, and community-based online channels. All activities can be completed remotely using the Folia Health app, the single site for this study. This app-based study aims to comprehensively assess patient-reported symptom burden, treatment use patterns, and impacts of PNH on health and FACIT-Fatigue through self-reported home-reported outcomes (HROs). Participants will track symptoms and treatment use, including recently approved treatments (e.g., iptacopan, danicopan, crovalimab). HROs consist of participants' self-identified symptoms and personalized treatment plan that are tracked longitudinally against self-reported baselines. Semi-structured interviews and collaborative feedback sessions with PNH patients and clinicians yielded a comprehensive outcomes inventory for tracking key health outcomes specific to PNH. This inventory includes the ability to track infusion treatments and denote flare-ups in fatigue. Participants can customize their data collection to track symptoms in additional domains beyond those initially suggested (e.g., respiratory or immune). At enrollment, participants report baseline health status and select their relevant symptoms and treatments to routinely track for 6 months. Monthly in-app surveys will collect data on overall health and the FACIT- Fatigue. The Folia app allows participants to visualize symptoms trends, set treatment reminders, and generate reports for their care team. Results: Enrollment began on June 11, 2024. As of July 22, 2024, an interim data analysis was conducted on 20 participants; 65% (n=13) enrolled through online community-based channels and 35% (n=7) enrolled through clinic referrals. Participants selected 37 distinct symptoms and measurements and 26 distinct treatments to track over the 6-month period. The most common symptoms selected at baseline include fatigue (n=19), brain fog (n=17), and dark colored urine (n=15). PNH treatments selected for tracking include iptacopan (n=9), ravulizumab (n=5), eculizumab (n=4), and pegcetacoplan (n=3). The mean baseline FACIT- Fatigue score (n=18) was 35.7 and the median was 40 (IQR= 16). Further descriptive analyses stratified by primary treatment use will be conducted assessing characteristics of symptom burden, satisfaction with treatments-in-use, and self-reported impact on HRQoL. Conclusions: Initial interim baseline data of recently enrolled participants with PNH show a variable disease experience. This app-based, observational study aims to establish a new real-world data source to understand patient priorities related to symptom variability, treatment patterns and preference, and impacts of condition management on HRQoL.
Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
Zanwar, Saurabh , Abdallah, Nadine , Seth, S D , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Lin, Yi , Hwa, Yi L. , Hobbs, Miriam, Fonder, Amie , Kumar, Shaji , Bolarinwa, Abiola , Seth, Sukriti, Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Muchtar, Eli , Gonsalves, Wilson I. , Dingli, David , Leung, Nelson , Cook, Joselle , Binder, Moritz , Rogers, Michelle G., Jevremović, Dragan , Rajkumar, S. Vincent

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4716-4716

10.1182/blood-2024-211755 Get It

Introduction: Measurable residual disease (MRD) is a well-validated prognostic marker and interim outcomes measure in patients with multiple myeloma (MM). Despite its broad acceptance as a robust prognostic marker, the MRD status is only available down the treatment line, and there is limited information on the markers at diagnosis that can predict achievement of MRD negativity post-transplant. This study explored the relationship between baseline risk factors and post-autologous stem cell transplantation (post-ASCT) MRD status, as well as the combined impact of these baseline factors and post-ASCT MRD status on progression-free survival (PFS) and overall survival (OS). Patients and Methods: We conducted a retrospective, single-center study of patients achieving at least VGPR after ASCT between 01/01/2016 and 12/30/2023, majority (n=814, 98%) received ASCT in the frontline setting. MRD testing was performed between days 60-100 post-transplant using next-generation flow cytometry with a sensitivity of at least 1x10^5 nucleated cells (minimum 2x10^6 cells assessed). Treatment response and disease progression were determined by IMWG criteria. High-risk disease (HRD) was defined as presence of International Staging System ISS stage 3, high lactate dehydrogenase, 1q gain, 17p deletion, or t(4;14) chromosomal abnormalities. We calculated PFS/OS from transplant day 0 to first documented event (progression or death). Categorical variables were compared using chi-square and Fisher's exact tests. Non-parametric tests compared continuous variables, and logistic regression analyses tested associations between clinical/lab variables and MRD status post-ASCT. Time-to-event analyses were performed using Kaplan-Meier and compared using log-rank test. Multivariable analyses were conducted using the Cox regression model. Result: The study cohort included 831 newly diagnosed MM patients. The median follow-up for the cohort was 50 months (95% CI: 48-51). 48% (n=402) achieved MRD negativity (MRD-neg) post-ASCT. Univariate analysis demonstrated that R2-ISS stage, depth of response pre-ASCT, and presence of t(11;14) to be associated with worse MRD-negativity rates. Multivariate analysis revealed that t(11;14) significantly decreased the odds of MRD-negativity (p<0.0001, OR=0.4, 95% CI: 0.3-0.6) and a deeper pre-ASCT response was associated with increase odd of MRD-negativity OR-4.7 (95%CI 3.2-7.4) p<0.0001. Patients with MRD-positive disease post-transplant had an inferior estimated median PFS of 57.6 months (95% CI: 49-69) with a 5-year PFS of 49% (95% CI: 43-56), compared to an estimated median PFS of 83.3 months (95% CI: NA) and a 5-year PFS of 66% in MRD-negative patients (p<0.0001, HR=1.9, 95% CI: 1.5-2.5). Similarly, MRD positivity was associated with an inferior OS [estimated median of 92.6 months (95% CI NA) ,5-year OS 76% (95%CI 72-82) for MRD-pos vs. Median OS NR, 5-year OS 85%(95%CI NA) in MRD-neg; p=0.003, HR=1.69, 95% CI: 1.2-2.38)]. In MRD-neg patients, a baseline bone marrow plasma cells BMPC% >60% was significantly associated with worse PFS (HR=1.9, 95% CI: 1.26-2.99; p<0.01). High-risk disease was not associated with an inferior PFS or OS in patients with MRD-negativity. For MRD-neg patients, estimated median PFS was not reached for those without HRD, 5-year PFS was 66% (95%CI 51-85), compared to 83 months(95%CI 65-NA) for those with HRD, 5-year PFS was 65%(95%CI57-74), p=0.6441. The median OS was not reached in either group (p=0.07). Five-year OS was 94% (95%CI 86-100) in MRD-neg without HRD vs. 81%(95%CI 75-87) with HRD (p=0.07). In MRD-pos patients, median PFS was 81 months (95%CI 58-NA) for those without HRD, 5-year PFS of 59% (95%CI 46-77), compared to PFS of 41 months(95%CI 36-52) for those with HRD ,5-year PFS of 39% (95%CI 31.3-47) , p=0.003. Median OS was not reached in MRD-pos patients without HRD, but it was 59.8 months ( for those with HRD (p=0.0012). Five-year OS was 94% (95%CI 89-99) in MRD-pos without HRD vs. 67%(95%CI 60-74) with HRD (p<0.0001). For every 1 log increase in the residual cell % on MRD testing in MRD-pos patients, the hazard ratio for PFS increased by 42% (p=0.0002, HR=1.42, 95% CI: 1.2-1.7). Conclusion: Patients with t(11;14) have a reduced likelihood of achieving MRD negativity post-ASCT, whereas high-risk cytogenetics did not impact MRD-negativity rates. Achievement of MRD negativity post-ASCT mitigates the impact of high-risk characteristics.
Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
Abel, Gregory A. , Baghdadi, Tareq Al, Bejar, Rafael, Deeg, H. Joachim , Foran, James M. , Liu, Jane Jijun, Saber, Wael , Zhang, Ling , Borchert, Christine, Padron, Eric , DiFronzo, Nancy, Baghdadi, Tareq Al , Dezern, Amy Elizabeth , Otterstatter, Michael , Gillis, Nancy , Bejar, Rafael , Komrokji, Rami S. , Lindsley, R Coleman , Moscinski, Lynn C. , Sherman, Seth , Walter, Matthew J , Sekeres, Mikkael A.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1831-1831

10.1182/blood-2024-201613 Get It

Introduction Knowledge of epidemiologic risk factors, clonal changes associated with MDS development from precursor states, and evolution from one MDS state to another (lower- (LR) or higher-risk (HR) disease or leukemia (AML)) are largely limited to retrospective studies, which may not reflect the true MDS spectrum. The MDS NHS is an established prospective cohort of patients (pts) with suspected MDS enrolled at diverse US sites. Extensive clinical data and biospecimens are collected at baseline and throughout follow-up (F/U), in real time, as pts are followed for life. Here, we assess rates and potential predictors of progression providing a foundation for precise stratification across the MDS spectrum, which may ultimately guide intervention. Methods At baseline, all MDS NHS pts have central pathology review and those assigned to MDS, MDS/MPN overlap, AML<30% blasts, or at-risk of MDS (AR-MDS: CCUS and other at-risk) are followed prospectively. We compared AR-MDS with LR-MDS (MDS and MDS/MPN overlap with IPSS-R ≤ 3.5) and HR-MDS (MDS and MDS/MPN overlap with IPSS-R > 3.5). We defined disease progression as any F/U diagnosis of worsening disease or documented disease-related death. Rates of disease progression were compared between groups using survival analysis methods for cumulative incidence incorporating non-disease death as a competing risk. Associations between progression and predictor variables were explored using univariate tests of association and multivariable survival (Cox regression) models for time-to-progression and logistic models for probability of progression (yes/no). Results The MDS NHS enrolled 2051 pts during June 2016-February 2024, with 54% (1111, above categories) followed prospectively. Median F/U is 1.7 yrs (IQR: 0.8-3.1 yrs, max: 7.9 yrs). For the current analysis, 582 MDS and 505 AR-MDS pts were included. Compared to AR-MDS, MDS patients were more often male (70% v 61%, p<0.01), older (median age: 75 v 72 years, p<0.01), and had lower baseline hemoglobin (median: 10.1 v 11.9 g/dL, p<0.001), platelets (median: 124 x109 v 146 x109 cells/L, p<0.001), and absolute neutrophil counts (median: 1.9 x109 vs 2.8 x109 cells/L, p<0.001). F/U time was similar among AR-MDS and MDS (median: 1.9 vs 1.6 yrs), with both groups having a 75th percentile of 3 yrs and maximum of 7 yrs. A total of 331 deaths were observed (30%), with 145 (44%) of these due to causes related to MDS (myeloid disease and/or cardiovascular disease). Overall, 18.5% had disease progression, with annual rates of 8% (MDS) and 2% (AR-MDS) (p<0.01). Among HR-MDS, progression rates were greatest in the 1st year following diagnosis (33%) and declined thereafter, whereas progression rates remained between 5-8% for LR-MDS and 1-3% for AR-MDS over 5 yrs of F/U. AR-MDS had similar rates of progression within the first 3 yrs from diagnosis as MDS with the lowest IPSS-R category. Among AR-MDS, low hemoglobin (hazard ratio, HR [95% CI]=3.2 [1.4-7.3], p<0.01) was significantly associated with progression. Among MDS, low hemoglobin (HR=4.0 [2.2-7.0], p<0.001), low platelet count (HR=3.1 [1.7-5.6], p<0.001) and higher numbers of mutations (HR=1.13 [1.0-1.2], p<0.01) were significantly associated with progression. Due to the low rate of progression in AR-MDS, meaningful comparisons of mutations could not be completed. In MDS, univariate analyses showed that somatic mutation prevalence in gene pathways for transcription, cell cycle and RAS signaling, and in genes TP53, BCOR, SF3B1, DDX41, PTPN11, SETBP1, and JAK2 were significantly associated with the probability of progression (p<0.05 in all). In multivariable models, adjusting for patient age, sex, and MDS risk level, the probability of progression (PP) was significantly higher among those with vs without somatic mutations in BCOR (PP=63% vs 29%, p=0.004), PTPN11 (PP=67% vs 29%, p=0.009), SETBP1 (PP=61% vs 30%, p=0.02), JAK2 (PP=59% vs 30%, p=0.02), DDX41 (PP=56% vs 30%, p=0.03) and TP53 (PP=43% vs 29%, p=0.04). Conclusions In this large prospective cohort of MDS and pts at risk for MDS, the annual rate of any disease progression was 8% among MDS and 2% among AR-MDS, lower than some retrospective series. Specific cytopenias and genetic factors associated with progression were identified. The MDS NHS provides an incomparable opportunity to address the critical clinical challenges of management and prevention of MDS progression across its spectrum.
Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
Foran, James M. , Bejar, Rafael, Baghdadi, Tareq Al, Deeg, H. Joachim , Abel, Gregory A. , Liu, Jane Jijun, Saber, Wael , Vidrine, Damon J. , Borchert, Christine, DiFronzo, Nancy, Venugopal, Sangeetha , Otterstatter, Michael , Dezern, Amy Elizabeth , Walter, Matthew J , Bejar, Rafael , Komrokji, Rami S. , Lindsley, R Coleman , Madanat, Yazan F. , Moscinski, Lynn C. , Vidrine, Jennifer Irvin , Zhang, Ling , Sherman, Seth , Gillis, Nancy , Sekeres, Mikkael A.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4597-4597

10.1182/blood-2024-206034 Get It

Introduction: Myelodysplastic syndromes (MDS) occur due to the acquisition of mutational events over time. Tobacco smoking is a risk factor for MDS and has been associated with distinct genetic mutations in solid cancers. We investigated the association between smoking intensity and duration and the number and types of genetic mutations in MDS using a large prospective cohort. Methods: The prospective NHLBI/NCI National MDS Natural History Study includes individuals with suspected or recently diagnosed MDS enrolled between June 2016-August 2023. Patient (Pt) bone marrow samples underwent central pathology review, resulting in diagnoses including MDS, MDS/myeloproliferative neoplasm overlap (MDS/MPN), or precursor conditions, such as clonal cytopenia of undetermined significance (CCUS). Self-reported smoking data were collected at enrollment. Smoking intensity (i.e., light, medium, and heavy) was defined per CDC definitions. Included mutations were those manually annotated to be pathogenic for MDS. Mutation frequency and prevalence, as well as associations with smoking history and other key covariates, were assessed using univariate tests of association and multivariable regression models for counts and proportions. Rates of disease progression were compared between groups using survival analysis methods for cumulative incidence incorporating non-disease death as a competing risk. Results: Of 1898 evaluable pts, 52% (N=979) had a history of cigarette smoking [MDS: 58% (252/436), MDS/MPN: 57% (52/91), CCUS: 57% (230/405)], and 18% still smoked at diagnosis. The mean ± SD cigarettes per day was 15.8 ± 12.5 and the mean ± SD smoking years was 29.8 ± 16.9 years. Compared to non-smokers, smokers were more often males (68% v 54%, p<0.001) in the 70-79 year age group (45% v 34%, p<0.001). Similar proportions of those with and without a smoking history had MDS (41% v 37%, respectively). Within MDS, there was no association between smoking and MDS prognostic risk per revised international prognostic scoring system. Compared to light smokers [1-10 pack-years (PY)], heavy smokers (30+ PY) were more often male (81% v 62%, p<0.001) and had higher rates of cardiovascular disease (38% v 20%, p<0.001). In univariate analyses, smokers and non-smokers had similar numbers of mutations (mean ± SD: 2.0 ± 2.7 in both groups). Pts with CCUS had the least number of mutations (1.5 ± 1.2), followed by MDS (2.3 ± 1.8), and MDS/MPN overlap (3.3 ± 1.8). Within disease groups, smokers and non-smokers had similar numbers of mutations. Mutation prevalence was higher among smokers v non-smokers in gene pathways for chromatin modification (15% v 11%, p<0.01) and RNA splicing (26% v 19%, p<0.001) and for individual genes ASXL1 (12% v 8%, p<0.01), SF3B1 (9% v 6%, p<0.05), U2AF1 (6% v 3%, p<0.05) and ZRSR2 (2% v 1%, p<0.05). In multivariable regression models, after adjustment for sex, age and disease group, smokers had significantly more mutations on average than non-smokers (2.0 v. 1.4, p=0.04). Moreover, the number of mutations increased significantly with PY smoked (p=0.006), and those at the 75th and 90th percentiles of PY had 1.8 and 3.5 times the number of mutations, respectively, compared to non-smokers, indicating a dose-response relationship. After adjustment, mutation prevalence increased with PY smoked in the gene pathways for chromatin modification and RNA splicing (p<0.03 for both) and for the genes ASXL1 and ETNK1 (p<0.05 in both cases). The five-year cumulative incidence of disease progression was significantly higher among long-term smokers compared to non-smokers/those with shorter smoking history (mean [95% CI] proportion progressed, 20+ years vs <20 years smoking: 27% [19%-36%] vs 18% [13%-24%], p < 0.05). Overall survival was significantly lower for smokers compared to non-smokers for CCUS pts [HR 1.91, 95% CI (1.03-3.55), p=0.04] but not for MDS [HR 1.21, 95% CI (0.53-1.30), p=0.41]. Conclusions: In this prospective, national cohort, tobacco smoking was associated with distinct genetic mutations related to MDS, suggesting smoking potentially contributes to its multi-step molecular pathogenesis. A dose-response relationship was also demonstrated, as was an association with progression and survival. Our data suggest that pts with a new MDS diagnosis who are also smokers should be counseled to stop smoking, as it appears to contribute to the acquisition of new genetic mutations that can lead to progression.
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Zile, Michael R. , Borlaug, Barry A. , Kramer, Christopher M. , Baum, Seth J. , Litwin, Sheldon E. , Menon, Venu , Ou, Yang , Weerakkody, Govinda J. , Hurt, Karla, Murakami, Masahiro, Group, for the SUMMIT Trial Study, Murakami, Masahiro , Packer, Milton , Borlaug, Barry A , Zile, Michael R , Kanu, Chisom , Packer, Milton , Group, for the SUMMIT Trial Study

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 10 | Pages: 656-668

10.1161/circulationaha.124.072679 | PMID 39556714 Get It

BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m 2 to tirzepatide (titrated up to 15 mg SC weekly; n=364) or placebo (n=367) added to background therapy for a median of 104 weeks (quartile 1, 66; quartile 3, 126 weeks). The primary end points were whether tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The current expanded analysis included sensitivity analyses of the primary end points, 6-minute walk distance, EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health score, New York Heart Association class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and 6-minute walk distance. RESULTS: Patients were 65.2±10.7 years of age; 53.8% (n=393) were female; body mass index was 38.2±6.7 kg/m 2 ; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 53.5±18.5; 6-minute walk distance was 302.8±81.7 m; and 53% (n=388) had a worsening heart failure event in the previous 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time to first event (hazard ratios, 0.41–0.67). At 52 weeks, tirzepatide increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points (95% CI, 3.3–10.6; P <0.001), 6-minute walk distance 18.3 meters (95% CI, 9.9–26.7; P <0.001), and EQ-5D-5L 0.06 (95% CI, 0.03–0.09; P <0.001). The tirzepatide group shifted to a more favorable Patient Global Impression of Severity Overall Health score (proportional odds ratio, 1.99 [95% CI, 1.44–2.76]) and New York Heart Association class (proportional odds ratio, 2.26 [95% CI, 1.54–3.31]; both P <0.001) and required fewer heart failure medications ( P =0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.17–2.28]; P =0.004). CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04847557.
Abstract 4145340: Health System Variability in Lipid Management for Patients with Atherosclerotic Cardiovascular Disease: An Analysis from Cv-MOBIUS
Shrader, Peter, Shoji, Satoshi , Fernández, Soledad, Arnold, Jonathan , Allred, Clint, Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Ahmad, Zahid , Kalich, Bethany , Fernandez, Soledad , Shah, Nishant , Martin, Seth S. , Chamberlain, Alanna M. , Shapiro, Michael D. , Effron, Mark B , Chrischilles, Elizabeth A. , Dhalwani, Nafeesa N , Jones, Laney K , Wojcik, Cezary , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4145340 Get It

Background: Nationally, many ASCVD patients fail to achieve an LDL-C <70 mg/dL, and uptake of both statin and non-statin therapies is low. The degree to which this varies across health systems is less clear. Methods: A cross sectional analysis was performed where lipid levels and lipid lowering therapies (LLT) were assessed using electronic health record data in patients with a previous diagnosis of ASCVD. The data was obtained across 14 US healthcare systems between 1/1/2021-12/31/2022. Proportions of patients with an active prescription of any statin, high intensity statin, ezetimibe, PCSK9i, and combination therapy (two or more agents) within 395 days of the most recent LDL-C value (index date) was evaluated overall and by participating site. Additionally, the proportion of patients with an LDL-C <70 mg/dL at the index date was also assessed. Results: Across 14 health systems, 1,118,623 patients with ASCVD were identified (median 61,840 per health system, range 8,161-182,315). Overall, 675,776 (60.4%) had an LDL-C level in the past year (range 39.1% - 70.8%). Of those with a lipid level, achievement of LDL-C <70 mg/dL ranged from 34.6-47.2%. In total, 42.6% were on any statin, 20.1% were on a high intensity statin, 4.3% on ezetimibe, and 1.2% on a PCSK9i. Only 2.9% were on combination therapy of a statin with ezetimibe or a PCSK9i. Variability was seen across health systems in utilization of each of these therapies, however even in the highest performing health systems, LLT uptake and achievement of LDL-C < 70mg/dL remained low ( Figure). Conclusion: Variability in utilization of LLT in ASCVD patients between health systems suggests that system-level factors may impact achieving guideline-based LDL-C goals. Despite the variability, the highest proportion of patients achieving an LDL-C <70mg/dL remained under 50% indicating the need for aggressive implementation efforts.
Abstract 4141523: Human-Centered Design to Tailor Telehealth Cardiac Rehabilitation to Diverse Populations: The MCNAIR Study
Oanesa, Rae Denise , Ali, Yehia Z, Khoury, Shireen , Lageza, Vanessa, McNair, Patricia, Merritt, Greg, Nallamothu, Brahmajee K. , Atluri, Namratha , McNair, Patricia, Mishra, Sonali R. , Forman, Daniel E. , Spaulding, Erin M. , Brewer, LaPrincess C. , Golbus, Jessica R , Martin, Seth S. , Beatty, Alexis L.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4141523 Get It

Background: Delivering cardiac rehabilitation (CR) by telehealth may increase participation and promote equitable access to CR. Our objective was to tailor a patient-centered telehealth CR program to diverse populations. Methods: We recruited participants with varying CR experience (e.g. attended >1 session, did not attend CR, and caregivers) between January and September 2023 from four US academic medical centers. Participants engaged in human-centered design sessions on CR perspectives and a proposed telehealth CR program. Sessions were qualitatively analyzed using rapid template analysis with pre-selected behavioral science constructs and other emergent codes. Based on participant feedback, we iteratively revised the telehealth CR program and created an implementation toolkit. Results: Among 21 participants (76% ≥65 years, 50% female, 60% non-Hispanic White; 90% attended >1 session, 10% caregiver of a CR participant, 5% prefer not to answer), CR was overall regarded as valuable. Benefits included accountability, confidence, and feeling better. Social support was appreciated from family, friends, program co-participants, and CR staff. Participants emphasized the importance of early goal setting, accountability, and program individualization. Participants thought that using technology for telehealth CR could be helpful for accountability, facilitating relationships, and convenience. However, some participants had concerns about safety, especially at the start of their telehealth program, and desired checks such as a monitoring device or observation of exercise over video. Through human-centered design, safety protocols and technology training were developed, which participants thought addressed their concerns about participating in telehealth CR. The implementation toolkit informed by human-centered design included a participant journey, safety plan, home exercise plan for use during and after CR, and scripts for technology training and telehealth visits. Selected quotes are presented in Figure 1. Conclusions: We developed a patient-centered telehealth CR program and implementation toolkit. Future research will test the comparative effectiveness of in-person and telehealth CR on patient-centered outcomes.
Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future
Keegan, B. Mark , Absinta, Martina , Henry, Roland G. , Klawiter, Eric C. , Kolind, Shannon , Krieger, Stephen, Laule, Cornelia , Lincoln, John A. , Papinutto, Nico , Smith, Seth A., Flanagan, E P , Henry, Roland G , Klawiter, Eric C , Laule, Cornelia , Messina, Steven, Traboulsee, Anthony , Keegan, B Mark , Kollind, Shannon H , Cohen-Adad, Julien , Flanagan, Eoin P. , Messina, Steven A. , Oh, Jiwon

Mayo Clinic

Brain Communications | November 6, 2024 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcae395 | PMID 39611182 Get It

Abstract Spinal cord disease is important in most people with multiple sclerosis, but assessment remains less emphasized in patient care, basic and clinical research and therapeutic trials. The North American Imaging in Multiple Sclerosis Spinal Cord Interest Group was formed to determine and present the contemporary landscape of multiple sclerosis spinal cord evaluation, further existing and advanced spinal cord imaging techniques, and foster collaborative work. Important themes arose: (i) multiple sclerosis spinal cord lesions (differential diagnosis, association with clinical course); (ii) spinal cord radiological–pathological associations; (iii) ‘critical’ spinal cord lesions; (iv) multiple sclerosis topographical model; (v) spinal cord atrophy; and (vi) automated and special imaging techniques. Distinguishing multiple sclerosis from other myelopathic aetiology is increasingly refined by imaging and serological studies. Post-mortem spinal cord findings and MRI pathological correlative studies demonstrate MRI’s high sensitivity in detecting microstructural demyelination and axonal loss. Spinal leptomeninges include immune inflammatory infiltrates, some in B-cell lymphoid-like structures. ‘Critical’ demyelinating lesions along spinal cord corticospinal tracts are anatomically consistent with and may be disproportionately associated with motor progression. Multiple sclerosis topographical model implicates the spinal cord as an area where threshold impairment associates with multiple sclerosis disability. Progressive spinal cord atrophy and ‘silent’ multiple sclerosis progression may be emerging as an important multiple sclerosis prognostic biomarker. Manual atrophy assessment is complicated by rater bias, while automation (e.g. Spinal Cord Toolbox), and artificial intelligence may reduce this. Collaborative research by the North American Imaging in Multiple Sclerosis and similar groups with experts combining distinct strengths is key to advancing assessment and treatment of people with multiple sclerosis spinal cord disease.